» Articles » PMID: 422981

Macrophages in Experimental and Human Brain Tumors. Part 2: Studies of the Macrophage Content of Human Brain Tumors

Overview
Journal J Neurosurg
Specialty Neurosurgery
Date 1979 Mar 1
PMID 422981
Citations 113
Authors
Affiliations
Soon will be listed here.
Abstract

The authors have analyzed 47 tumors of the central nervous system (11 glioblastomas, nine meningiomas, three medulloblastomas, 12 assorted primary neural tumors, and 12 brain metastases) for their content of macrophages. Cell suspensions were prepared by enzymatic digestion and macrophages were quantitated by IgGEAC rosette formation. Adsorption of sensitized indicator cells (EA) to sections of tumor was used as a measure to determine the distribution of IgGFc receptor-positive cells within the tumors and to serve as a control for selective release of IgGFc receptor-positive cells by enzyme digestion. The 11 glioblastomas had a mean macrophage content of 45% (range: 8% to 78%), the nine meningiomas had a mean of 44% (range: 5% to 81%), the three medulloblastomas a mean of 6% (range 2% to 15%), and the metastatic tumors a mean of 24% (range: 4% to 70%). Adsorption of EA demonstrated that IgGFc receptor-positive cells were distributed throughout the tumor mass, although different types of patterns were observed. There was an excellent correlation between the percent of IgGEAC positive cells in suspensions and the extent of EA adsorption to the tumor sections. Compared to systemic neoplasms, most nervous system tumors have a high macrophage content. It is possible that the high macrophage content of brain tumors is related to their immunogenicity, and may be a partial explanation for tha rarity of brain-tumor metastases.

Citing Articles

Opportunities and challenges for patient-derived models of brain tumors in functional precision medicine.

Mann B, Artz N, Darawsheh R, Kram D, Hingtgen S, Satterlee A NPJ Precis Oncol. 2025; 9(1):47.

PMID: 39953052 PMC: 11828933. DOI: 10.1038/s41698-025-00832-w.


FLASH radiation reprograms lipid metabolism and macrophage immunity and sensitizes medulloblastoma to CAR-T cell therapy.

Ni H, Reitman Z, Zou W, Akhtar M, Paul R, Huang M Nat Cancer. 2025; .

PMID: 39910249 DOI: 10.1038/s43018-025-00905-6.


Peptide-drug conjugates repolarize glioblastoma-associated macrophages to resensitize chemo-immunotherapy of glioblastoma.

Li Z, Jiang S, Wang J, Li W, Yang J, Liu W Sci Adv. 2025; 11(3):eadr8841.

PMID: 39823328 PMC: 11740939. DOI: 10.1126/sciadv.adr8841.


Immunophenotypic Profile of Adult Glioblastoma IDH-Wildtype Microenvironment: A Cohort Study.

Asioli S, Gatto L, Vardy U, Agostinelli C, Di Nunno V, Righi S Cancers (Basel). 2024; 16(22).

PMID: 39594814 PMC: 11592556. DOI: 10.3390/cancers16223859.


Microglia induce an interferon-stimulated gene expression profile in glioblastoma and increase glioblastoma resistance to temozolomide.

Sorensen M, Olsen R, Burton M, Kavan S, Petterson S, Thomassen M Neuropathol Appl Neurobiol. 2024; 50(6):e13016.

PMID: 39558550 PMC: 11618491. DOI: 10.1111/nan.13016.